GlassScriptPhysician profile
Timothy Edward Oboyle
NPI 1720080088
$970.31
in general payments reported to CMS, 2019-2025
14 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.16 · 2020: $176 · 2021: $159 · 2022: $91.28 · 2023: $123 · 2024: $206 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $256.68 | 2019-2025 | Rocklatan, Clareon |
| Genentech USA, INC. | $181.94 | 2023-2025 | Vabysmo |
| Glaukos Corporation | $149.55 | 2020 | |
| Amgen INC. | $88.92 | 2024-2025 | Tepezza |
| Allergan, INC. | $76.10 | 2019-2021 | |
| Oyster Point Pharma, INC. | $43.44 | 2022-2025 | Tyrvaya |
| Abbvie INC. | $37.45 | 2024 | |
| Aerie Pharmaceuticals, INC. | $29.40 | 2021 | |
| Apellis Pharmaceuticals, INC. | $22.38 | 2023 | |
| Sun Pharmaceutical Industries INC. | $22.16 | 2021 | |
| Horizon Therapeutics Plc | $19.55 | 2023 | Tepezza |
| Astellas Pharma US INC | $16.97 | 2025 | Izervay |
| Rxsight INC | $13.86 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Iridex Corporation | $11.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Oboyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.